HK biotech IPOs exhibit symptoms of overvaluation

Hong Kong saw its second biotechnology listing this week, as BeiGene floated on the city’s stock exchange. But two days after listing it was under water and was followed by a double-digit dive by Ascletis Pharma, the sector’s debut issuer. The state of both stocks are a warning sign for future biotech issuers to rein in valuations, say ECM bankers. Jonathan Breen reports.

  • By Jonathan Breen
  • 09 Aug 2018
Chinese drug manufacturer BeiGene listed on the Hong Kong Stock Exchange on Wednesday through a HK$7.1bn ($904.5m) follow-on offering. The firm also trades on the Nasdaq and ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Panda Bonds Top Arrangers

Rank Arranger Share % by Volume
1 Bank of China (BOC) 21.85
2 China Merchants Securities Co 14.67
3 Industrial and Commercial Bank of China (ICBC) 14.44
4 Agricultural Bank of China (ABC) 8.89
5 China Securities 7.41

Bookrunners of Asia-Pac (ex-Japan) ECM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 CITIC Securities 9,346.38 46 7.88%
2 Goldman Sachs 8,791.68 35 7.42%
3 Morgan Stanley 6,937.95 46 5.85%
4 China International Capital Corp Ltd 6,923.83 42 5.84%
5 UBS 6,281.96 46 5.30%

Bookrunners of Asia Pacific (ex-Japan) G3 DCM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 HSBC 20,690.46 181 8.39%
2 Citi 15,145.16 114 6.14%
3 JPMorgan 12,957.39 88 5.25%
4 Standard Chartered Bank 10,112.16 101 4.10%
5 Bank of China 9,370.02 117 3.80%

Asian polls & awards